James Harding

1 month ago | blackcircles.com | James Harding

Squeaky brakes might seem like a minor annoyance, but they could be a warning sign that your braking system needs attention. Learn what causes the squeal when to call in the pros. Squeaky Brakes: Diagnostics TableTo get straight to the point, here are some of the most common causes of squeaky brakes, with a note on the severity of the issue and recommended actions.

1 month ago | observer.co.uk | James Harding

He may have been low-ego, but the Times journalist was probably the most important investigative reporter of his generation Andrew Norfolk was probably the most important investigative reporter of his generation. He wasn’t, though, what you might expect of a journalist. He was low-ego and rather shy. His great qualities were empathy and humility. He felt for the people he wrote about; sometimes when he told you their stories and relived the horrors he’d heard, he shook. He taught us all patience.

Jan 30, 2025 | targetedonc.com | James Harding

January 30, 2025James J. Harding, MD, discusses the remaining unmet needs in the first-line (1L) treatment space for unresectable hepatocellular carcinoma (uHCC) and how 1L immunotherapy (IO) combinations like nivolumab plus ipilimumab (NIVO + IPI) may help address these gaps, while highlighting unanswered questions and offering clinical pearls for managing uHCC. Video content above is prompted by the following:What are some remaining unmet needs in the 1L space for uHCC?

Jan 23, 2025 | targetedonc.com | James Harding

January 23, 2025James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for unresectable hepatocellular carcinoma (uHCC), considering factors such as efficacy, safety, and patient characteristics (eg, age) when selecting between first-line systemic immunotherapy (IO) regimens.

Jan 16, 2025 | targetedonc.com | James Harding

January 16, 2025James J. Harding, MD, compares the responses observed with nivolumab plus ipilimumab (NIVO + IPI) therapy in the CheckMate 9DW trial to other first-line (1L) immunotherapy (IO) regimens for unresectable hepatocellular carcinoma (uHCC), including the HIMALAYA 5-year update (STRIDE) and the IMbrave150 trial (atezolizumab [ATEZO] + bevacizumab [BEV]), highlighting differences in efficacy and treatment outcomes.